Literature DB >> 18703792

Treatment outcomes and long-term survival in patients with extensively drug-resistant tuberculosis.

Doh Hyung Kim1, Hee Jin Kim, Seung-Kyu Park, Suck-Jun Kong, Young Sam Kim, Tae-Hyung Kim, Eun Kyung Kim, Ki Man Lee, Sung Soon Lee, Jae Seuk Park, Won-Jung Koh, Chang-Hoon Lee, Ji Yeon Kim, Tae Sun Shim.   

Abstract

RATIONALE: The increasing worldwide incidence of extensively drug-resistant tuberculosis (XDR-TB) has emerged as a threat to public health and tuberculosis (TB) control. Treatment outcomes have varied among studies, and data on long-term survival are still scarce.
OBJECTIVES: To retrospectively assess the burden, clinical characteristics, treatment outcomes, and long-term survival rate of patients with XDR-TB in a cohort of patients with HIV-negative multidrug-resistant tuberculosis (MDR-TB) in South Korea.
METHODS: Medical records were reviewed of patients newly diagnosed with or retreated for MDR-TB from 2000 to 2002. The cohort was monitored for 3 to 7 years after the initiation of treatment. Initial treatment outcomes and cumulative survival rates were analyzed, and predictors of treatment success and survival were defined.
MEASUREMENTS AND MAIN RESULTS: Of 1,407 patients with MDR-TB 75 (5.3%) had XDR-TB at treatment initiation. The default rate was high (453/1,407; 32%), and patients with XDR-TB had lower treatment success (29.3 vs. 46.2%; P = 0.004) and higher all-cause (49.3 vs. 19.4%; P < 0.001) and TB-related disease mortality (41.3 vs. 11.8%; P < 0.001) than other patients with MDR-TB. The presence of XDR-TB significantly affected treatment success (odds ratio, 0.23; 95% confidence interval [CI], 0.08-0.64; P = 0.005), all-cause mortality (hazards ratio, 3.25; 95% CI, 1.91-5.53; P < 0.001), and TB-related mortality (hazards ratio, 4.45; 95% CI, 2.48-8.00; P < 0.001) on multivariate analyses.
CONCLUSIONS: XDR-TB occurred in a substantial proportion of patients with MDR-TB in South Korea, and was the strongest predictor of treatment outcomes and long-term survival in patients with MDR-TB. Adequate TB control policies should be implemented to prevent the further development and spread of drug resistance.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18703792     DOI: 10.1164/rccm.200801-132OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  56 in total

Review 1.  The chemical biology of new drugs in the development for tuberculosis.

Authors:  Clifton E Barry; John S Blanchard
Journal:  Curr Opin Chem Biol       Date:  2010-05-07       Impact factor: 8.822

2.  An adjunctive therapeutic vaccine against reactivation and post-treatment relapse tuberculosis.

Authors:  Toshiko Miyata; Chan-Ick Cheigh; Nicola Casali; Amador Goodridge; Olivera Marjanovic; Lon V Kendall; Lee W Riley
Journal:  Vaccine       Date:  2011-11-08       Impact factor: 3.641

Review 3.  Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis.

Authors:  Karen R Jacobson; Dylan B Tierney; Christie Y Jeon; Carole D Mitnick; Megan B Murray
Journal:  Clin Infect Dis       Date:  2010-07-01       Impact factor: 9.079

4.  Imaging tuberculosis with endogenous beta-lactamase reporter enzyme fluorescence in live mice.

Authors:  Ying Kong; Hequan Yao; Hongjun Ren; Selvakumar Subbian; Suat L G Cirillo; James C Sacchettini; Jianghong Rao; Jeffrey D Cirillo
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-21       Impact factor: 11.205

Review 5.  Surgical treatment of drug-resistant tuberculosis.

Authors:  Russell R Kempker; Sergo Vashakidze; Nelly Solomonia; Nino Dzidzikashvili; Henry M Blumberg
Journal:  Lancet Infect Dis       Date:  2012-02       Impact factor: 25.071

Review 6.  Drug-resistant tuberculosis: a worldwide epidemic poses a new challenge.

Authors:  Robert Loddenkemper; Barbara Hauer
Journal:  Dtsch Arztebl Int       Date:  2010-01-07       Impact factor: 5.594

7.  Prevalence and factors associated with tuberculosis treatment outcome among hazardous or harmful alcohol users in public primary health care in South Africa.

Authors:  K Peltzer; J S Louw
Journal:  Afr Health Sci       Date:  2014-03       Impact factor: 0.927

8.  Adjunctive surgery improves treatment outcomes among patients with multidrug-resistant and extensively drug-resistant tuberculosis.

Authors:  Medea Gegia; Iagor Kalandadze; Russel R Kempker; Matthew J Magee; Henry M Blumberg
Journal:  Int J Infect Dis       Date:  2012-03-17       Impact factor: 3.623

9.  Treatment Outcomes of Patients with Multidrug-Resistant Tuberculosis (MDR- TB) Compared with Non-MDR-TB Infections in Peninsular Malaysia.

Authors:  Omar Salad Elmi; Habsah Hasan; Sarimah Abdullah; Mat Zuki Mat Jeab; Zilfalil Ba; Nyi Nyi Naing
Journal:  Malays J Med Sci       Date:  2016-06-30

Review 10.  Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis.

Authors:  James C Johnston; Neal C Shahidi; Mohsen Sadatsafavi; J Mark Fitzgerald
Journal:  PLoS One       Date:  2009-09-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.